Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.92 - $25.42
Previous CloseN/A
Volume58.73K
Average Volume (3M)1.15M
Market Cap
$399.93M
Enterprise ValueN/A
Total Cash (Recent Filing)$471.39M
Total Debt (Recent Filing)$10.84M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 07, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding53,826,980
10 Day Avg. Volume2,207,494
30 Day Avg. Volume1,150,561
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.45
Price to Sales (P/S)0.00
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$49.67Price Target Upside568.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Prothena News
PremiumCompany Announcements
Prothena Corporation Reports Q1 2025 Financial Results
PremiumCompany Announcements
Prothena Reports 2024 Financial Results and 2025 Outlook---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPRX012 remains on track to deliver multiple data from its higher-dose MAD cohorts, aiming to strike a balance between optimal plaque clearance and ARIA incidence, which could bolster its position in the AD treatment landscape.
Survival BenefitBirtamimab might lead to a 50% reduction in mortality in the Mayo Stage four patients.
Therapeutic PotentialThe company's decision to explore higher doses with a once-monthly regimen underscores its confidence in the antibody’s therapeutic potential, positioning it as patient-friendly for Alzheimer's patients.
Bears Say
Investor SentimentAnalysts are lowering P/E multiples and increasing discount rates to better align with current investor sentiment and elevated cost of capital, resulting in a reduced price target.
Need For ValidationSignificant clinical validation is still needed to better understand the efficacy and safety of PRX012.
Statistical SignificanceThe Phase 2b PADOVA study conducted by Roche narrowly missed the statistical significance in the primary endpoint of time to confirmed motor progression.
---
Ownership Overview
13.43% Insiders
30.50% Mutual Funds
0.14% Other Institutional Investors
47.67% Public Companies and
Individual Investors
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $6.92 and its highest was $25.42 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $399.93M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 07, 2025 which is in 86 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 08, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.97 by -$0.15.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.99.
How many shares outstanding does Prothena have?
Prothena has 53,826,980 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.97. Following the earnings report the stock price went up 4.648%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
---
Prothena Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.67 (568.51% Upside)
$49.67 (568.51% Upside)
Hedge Fund Trend
Decreased
By 35.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $48.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.22%
12-Months-Change
Fundamentals
Return on Equity
-23.46%
Trailing 12-Months
Asset Growth
-20.52%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
---
PRTA Company Deck
---
PRTA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced outlook for Prothena. While there are significant opportunities for growth through its robust portfolio and strategic partnerships, challenges remain, particularly with the dependency on future clinical trial successes and the narrow miss in prasinezumab's statistical significance.Read More>---
PRTA Stock 12 Month Forecast
Average Price Target
$49.67
▲(568.51% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
KalVista Pharmaceuticals
―
Replimune Group
―
Immunome
―
Bicara Therapeutics Inc.
―
---